Recombinant Protein Enginnering for Pulmonary - Brussels, België - Louvain Drug Research Institute - Université catholique de Louvain

Beschrijving

Recombinant Protein Enginnering for Pulmonary Delivery at UCLouvain, Brussels, and ULiège, Liège, Belgium:

• Réf

-
ABG-111090

• Sujet de Thèse 13/02/2023
• Financement public/privé
• Louvain Drug Research Institute
• Université catholique de Louvain
• Lieu de travail
• Brussels
• Belgique
• Intitulé du sujet
• Recombinant Protein Enginnering for Pulmonary Delivery at UCLouvain, Brussels, and ULiège, Liège, Belgium
• Champs scientifiques
• Biotechnologie
• Santé, médecine humaine, vétérinaire

• Mots clés

• Antibody fragments, Recombinant protein production, protein analysis, Cystic fibrosis, Inhalation
  Description du sujet:
• Neutrophil elastase significantly contributes to cystic fibrosis (CF) lung disease by causing lung damage and inflammation. The majority of adult patients with CF have

- _Pseudomonas aeruginosa_ chronic lung infections and
- _P. aeruginosa_ elastase further aggravates tissue destruction. The goal of this project is to generate protein-based nanomedicines able to inhibit the proteolytic activities of murine neutrophil elastase and
- _P. aeruginosa_ elastase and to assess these inhibitors as a local treatment in murine lung infection models of
- _P. aeruginosa_. The project will include recombinant protein production and purification, physicochemical and biological characterization of anti-elastase protein-based nanomedicines
- _ in vitro_ and their assessment
- _in vivo_ for pharmacokinetics and immunogenicity.-
Prise de fonction:

• 09/05/2023
  Nature du financement:
• Financement public/privé

Précisions sur le financement:

• 3.

5-year PhD fellowship funded by the Belgian National Fund for Scientific Research
Présentation établissement et labo d'accueil:

• Louvain Drug Research Institute
• Université catholique de Louvain

Rita Vanbever has developed an expertise in different areas of pulmonary drug delivery within the laboratory of Advanced Drug Delivery & Biomaterials of the Louvain Drug Research Institute (LDRI, UCLouvain) since 1998. The research of her group has dealt with the formulation of inhalation dry powders, the study of the pulmonary fate of diverse molecules following delivery to the lungs in vivo, the assessment of the potential of vaccine delivery to the lungs for protection against respiratory infections and lung cancer as well as the development of formulation strategies to sustain drug release within the lungs.


Site web:


Intitulé du doctorat:

• PhD in biomedical and pharmaceutical sciences
  Pays d'obtention du doctorat:
• Belgique

Etablissement délivrant le doctorat:

• UCLouvain
  Ecole doctorale:
• Pharmaceutical Sciences
• You have laboratory experience or a strong interest in molecular biology, recombinant protein production, purification and characterization, and in pharmaceutical research
• You are highly motivated and ready to work at two sites (Brussels and Liège).
• You have an ability to work independently and as part of a multidisciplinary team.
• You have obtained a master degree in bioengineering, biological sciences, or biomedical sciences.
• Laboratory experience in _in vivo_ studies is a plus.
• You possess good communicational skills in English. 13/03/2023